ZYBT logo

ZHENGYE BIOTECHNOLOGY-A

ZYBTNASDAQ
🏆 #4347 by market capUS Equity
$283.31▲ $18.73 (+6.61%)
Simulated price
🔔
Track ZYBT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.6%
7d▲ 20429.7%
14d▲ 20282.0%
30d▲ 16276.3%
ytd▲ 24535.7%
1y▲ 10902.3%
🏦Market Cap
$62M
Small Cap
📈Revenue Growth (YoY)
-37.6%
Declining
📊Gross Margin
8.3%
Thin
💵FCF Margin
48.8%
Strong
⚖️P/S Ratio
5.2x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
$278.92 – $287.26
52-Week Range
$0.62 – $8.01
Volume
$3.14B
Avg Volume
$2.43B
Shares Outstanding
47.4M
Next Earnings
Nov 9, 2026

Fundamentals Snapshot

Annual Revenue
$116M
Last Q Revenue
$53M
P/E Ratio
-5.9
P/S Ratio
5.2x
EPS (TTM)
$-1.50
Dividend Yield
0.00%

Why Investors Own ZYBT

  • ✓High-growth profile — revenue up +26.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 59% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ZYBT logo

ZHENGYE BIOTECHNOLOGY-A

ZYBT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$116M▼ −37.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
20.5%▼ −58.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$68M▼ −515.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$703K▼ −94.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$25M▲ +$43M YoY
StockOtter · stockotter.space

About ZHENGYE BIOTECHNOLOGY-A

Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$279.71
▼ −1.3% Downside
High Target$342.62
Low Target$253.56
Based on 29 analysts

Latest News & Updates

🚀
Reuters·2h ago

ZHENGYE BIOTECHNOLOGY-A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift ZYBT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

ZHENGYE BIOTECHNOLOGY-A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.